Table 2.

Logistic Regression Models Predicting Weekly Outcomes During the Acute Phase of the Intervention Program (n = 1,464 calls with 221 patients)

Variable	AOR	95 % CI	p value
Model 1, predicting antidepressant adherence
Minority	1.05	0.48–2.29	0.906
≥3 Comorbid conditions	1.59	1.01–2.48	0.042
Baseline depression symptom severity (PHQ-8)	0.95	0.91–0.99	0.009
Baseline nonadherence (MMAS)	0.71	0.55–0.91	0.007
Groupa	0.94	0.53–1.66	0.821
Week	1.11	0.99–1.24	0.082
Group X week	1.18	1.01–1.39	0.044
Model 2, predicting depression remissionb
Minority	1.70	0.90–3.18	0.100
≥ 3 Comorbid conditions	0.95	0.61–1.48	0.812
Baseline depression symptom severity (PHQ-8)	0.87	0.84–0.91	<0.001
Groupa	1.16	0.72–1.89	0.543
Week	1.08	1.00–1.18	0.065
Group X week	1.14	1.02–1.28	0.027
Model 3, predicting any bed days due to depression
Minority	0.86	0.40–1.87	0.712
≥ 3 Comorbid conditions	1.17	0.69–2.00	0.550
Baseline depression symptom severity (PHQ-8)	1.10	1.06–1.16	< 0.001
Groupa	0.70	0.38–1.28	0.248
Week	0.89	0.78–1.01	0.070
Group X week	0.96	0.81–1.14	0.628

AOR Adjusted odds ratio

MMAS Morisky Medication Adherence Scale

PHQ-8 Patient Health Questionnaire, 8-item version

^aControl and CP groups were coded as 0 and 1, respectively

^bBased upon the weekly PHQ-9 administered by IVR